Euroscreen Collaboration Delivers Successful Deorphanization of New GPCR Drug Target

Share Article

Euroscreen SA commented today on their recent, joint Nature publication with Novartis revealing the discovery of a novel therapeutic target for the treatment of immune disorders. A recent issue of Nature, described the identification of 7-25-dihydroxycholesterol (7,25-OHC) as the natural ligand for the EBI2 G-protein coupled receptor (‘GPCR’), also known as GPR183. The authors demonstrate that 7,25-OHC and closely related oxysterols activate EBI2 to modulate the activity of the immune system. A patent application has been filed for this discovery.

Euroscreen SA commented today on their recent, joint Nature publication with Novartis revealing the discovery of a novel therapeutic target for the treatment of immune disorders. A recent issue of Nature, described the identification of 7-25-dihydroxycholesterol (7,25-OHC) as the natural ligand for the EBI2 G-protein coupled receptor (‘GPCR’), also known as GPR183. The authors demonstrate that 7,25-OHC and closely related oxysterols activate EBI2 to modulate the activity of the immune system. A patent application has been filed for this discovery.

“This is a significant scientific event in our collaboration. Euroscreen granted Novartis an exclusive license to this target in 2008, and under the agreement Euroscreen is eligible to receive milestone payments as Novartis advances drug development efforts directed towards this target.” commented Jean Combalbert, CEO of Euroscreen.

Euroscreen has a proven track-record in the deorphanization of GPCR’s with EBI2 representing the 13th such success story in the company’s history. The Nature article describes the role of EBI2 in the modulation of immune function.

The article entitled “Oxysterols direct immune cell migration via EBI2” was published in the July 28th edition of Nature (Nature, vol 475, pp: 524-527).

About Euroscreen

Euroscreen (http://www.euroscreen.com) is a Belgium-based, private preclinical-stage Drug Discovery and Development Company targeting GPCR’s to provide first-in-class, small molecule drug candidates in the therapeutic areas of inflammation, metabolism and Women’s Health.

Euroscreen has a track-record on multiple innovative and proprietary chemical entities targeting G Protein Coupled Receptors (GPCR) due to its recognized know-how and expertise with these targets; having achieved in vivo proof of concept and efficacy in multiple preclinical programs. Euroscreen is now advancing programs of its own to clinical trials, and is actively seeking collaborations to advance its pharmaceutical candidates and further supplement its ongoing research and licensing partnerships with companies such as Boehringer-Ingelheim, Cephalon, Grunenthal, HGS, Johnson & Johnson, Monogram Biosciences, Novartis and Pfizer.

Our Company offers a broad patent portfolio for targets and screening tools to out-license to companies developing therapeutic drugs acting through targets as CCR5, ChemR23, GPR43 antagonists, GPR7/8, ORL1-R, FPRL2, P2Y4, P2Y11 and P2Y13.

Euroscreen provides GPCR custom testing services around the world which include target deorphanization/characterization, HTS-screening, lead optimization support, candidate profiling, through the services of its Euroscreen FAST Business Unit. (http://www.euroscreen-fast.com)

Contact:

Vincent Lannoy, PhD
Director, Euroscreen Legal and Intellectual Property
Tel +3271 348 500
Fax +32 71 348 519
http://www.euroscreen.com

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

ALFRED GRAY
Euroscreen SA
(716) 308-6693
Email >
Visit website